| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg | |||
| 100mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
IRAK-IN-6 targets interleukin-1 receptor-associated kinase 4 (IRAK4) as a selective inhibitor. IRAK4 is a serine/threonine kinase that plays a critical role in the signaling pathways of Toll-like receptors (TLRs) and interleukin-1 receptors (IL-1Rs), which are involved in inflammatory responses. By inhibiting IRAK4, the compound modulates inflammatory signaling.
|
|---|---|
| ln Vitro |
IRAK inhibitor 6 is the most potent of these drugs tested; potency additive, IRAK inhibitor 6 considerably improves potency against IRAK-4 [1].
In vitro, IRAK-IN-6 is a selective IRAK4 inhibitor with an IC50 of 0.16 μM. Its ability to inhibit IRAK4 activity and modulate inflammatory signaling has been characterized in various cell-based assays. The compound's selectivity for IRAK4 over other kinases has been confirmed. Its effects on cytokine production and inflammatory mediator release have been studied. |
| ln Vivo |
In vivo, IRAK-IN-6 is used in research on inflammatory signaling pathways. As an IRAK4 inhibitor, it may have potential therapeutic applications in inflammatory diseases. Studies have examined its effects in animal models of inflammation. Its pharmacokinetic properties and tissue distribution have been characterized.
|
| Enzyme Assay |
In cell-free biochemical assays, IRAK-IN-6 is evaluated for its inhibitory activity against IRAK4. Kinase activity assays measure the compound's ability to inhibit IRAK4-mediated phosphorylation. Its IC50 of 0.16 μM is determined using biochemical assays. Its purity (>95-98%) and molecular weight (396.46 g/mol) are characterized using analytical techniques.
|
| Cell Assay |
Cellular assays for IRAK-IN-6 involve evaluating its effects on IRAK4 activity and inflammatory signaling in immune cell lines. The compound's ability to inhibit IRAK4-mediated signaling is assessed. Its effects on cytokine production and inflammatory mediator release are studied. Its selectivity for IRAK4 over other kinases is confirmed.
|
| Animal Protocol |
Animal models for IRAK-IN-6 include models of inflammatory diseases. The compound is typically administered via injection or oral routes. Studies have examined its effects on inflammatory markers, disease progression, and survival. Its pharmacokinetic properties and tissue distribution have been characterized.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for IRAK-IN-6 show that the compound has a molecular weight of 396.46 g/mol with a molecular formula of C20H20N4O3S. The CAS number is 1042672-97-8. The compound is soluble in DMSO. It should be stored at -20°C. Standard handling procedures for kinase inhibitors apply.
|
| Toxicity/Toxicokinetics |
The toxicity profile of IRAK-IN-6 has not been extensively documented. As a kinase inhibitor, standard safety precautions for handling pharmaceutical research compounds apply. The compound is for research use only and not for human use.
|
| References | |
| Additional Infomation |
IRAK-IN-6 is a selective IRAK4 inhibitor with an IC50 of 0.16 μM. It is used in inflammatory signaling research. The compound has a molecular weight of 396.46 g/mol and formula C20H20N4O3S. The CAS number is 1042672-97-8.
|
| Molecular Formula |
C20H20N4O3S
|
|---|---|
| Molecular Weight |
396.46
|
| Exact Mass |
396.125
|
| CAS # |
1042672-97-8
|
| Related CAS # |
1042672-97-8;
|
| PubChem CID |
44449392
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Index of Refraction |
1.652
|
| LogP |
1.59
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
520
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
JQSRUVXPODZKAF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C20H20N4O3S/c1-26-18-11-15(24-7-9-27-10-8-24)4-5-16(18)22-19(25)17-13-28-20(23-17)14-3-2-6-21-12-14/h2-6,11-13H,7-10H2,1H3,(H,22,25)
|
| Chemical Name |
N-[2-Methoxy-4-(4-morpholinyl)phenyl]-2-(3-pyridinyl)-4-thiazolecarboxamide
|
| Synonyms |
IRAK-IN-6 IRAK IN 6 IRAKIN6 IRAK inhibitor 6
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~8.33 mg/mL (~21.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.83 mg/mL (2.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 8.3 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 + to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5223 mL | 12.6116 mL | 25.2232 mL | |
| 5 mM | 0.5045 mL | 2.5223 mL | 5.0446 mL | |
| 10 mM | 0.2522 mL | 1.2612 mL | 2.5223 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA